PART1 expression is associated with poor prognosis and tumor recurrence in stage I-III non-small cell lung cancer
Ming Li, Weiwei Zhang, Shenjun Zhang, Changhui Wang, Yinping Lin · Journal of Cancer · 2017
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2017
Abstract
Purpose: Long noncoding RNAs (lncRNAs) have been demonstrated as effective markers for cancer detection and prognosis prediction.The aim of this study was to determine whether tissue PART1 could be used as a biomarker for prognosis prediction of non-small cell lung cancer (NSCLC).Methods: PART1 expression was detected in 208 cases of stage I-III NSCLC specimens and adjacent normal tissues.The Cox proportional-hazards regression model was used to analyze the association between PART1 expression and overall survival (OS) and disease-free survival (DFS) of the patients.Results: It was found that the expression of PART1 was significantly up-regulated in 73.1% (152/208) stage I-III NSCLC specimens compared with adjacent normal tissues.High tissue PART1 expression was associated with shorter OS and could serve as an independent prognostic biomarker in stage I-III NSCLC patients (hazard ratio [HR] = 2.11, 95% CI = 1.18-3.78,P = 0.012).In addition, high tissue PART1 expression indicated poor DFS in stage I-III NSCLC patients (HR = 1.94, 95% CI: 1.37-2.76,P < 0.001).Conclusions: PART1 may prove to be a promising biomarker for prediction of survival and tumor recurrence in stage I-III NSCLC.
Open the resolved locator · 10.7150/jca.18848
Metadata licence: OpenAlex metadata (CC0)